Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites
Table 2
Main pharmacokinetic parameters of decoquinate in oily suspension with nano- and microparticle following single intramuscular injection at 120 mg/kg dose level in mice plasma ( = 2-3).
Main PK parameters following IM injection
Nano-DQ (0.43 µm) plasma
CV%
Micro-DQ (8.31 µm) plasma
CV%
(ng/ml)
36.58 ± 3.56
9.74
45.35 ± 8.09
17.84
(hr)
3.52 ± 0.13
3.82
3.22 ± 0.90
27.86
(ng⋅hr/ml)
10,385 ± 405
3.91
18,311 ± 926
5.06
(hr)
4.84 ± 0.71
14.61
3.24 ± 1.51
46.59
(hr)
751.01 ± 28.72
3.82
1,444.90 ± 118.56
8.21
Vss/F (L/kg)
12,155.69 ± 844.54
6.95
13,403.78 ± 447.67
3.34
CL/F (L/hr/kg)
11.56 ± 0.45
3.91
6.57 ± 0.32
4.84
Minimum inhibitory concentration (MIC) (ng/ml)
5.12 ± 0.18
3.51
5.12 ± 0.18
3.51
> MIC (hr)
624.25 ± 60.74 (3.72 weeks)
9.73
1375.00 ± 50.57 (8.18 weeks)
3.68
Value was calculated based on full causal prophylaxis effect for 8 weeks. IM: intramuscular; DQ: decoquinate; CV: coefficient of variation.
